Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Alzamend Neuro, Inc. (ALZN) had Stock-Based Compensation of $0.07M for the most recently reported fiscal quarter, ending 2025-10-31.
| Income Statement Financials | |
-- |
|
$-1.00M |
|
-- |
|
-- |
|
$1.00M |
|
$-1.00M |
|
$-0.00M |
|
$-1.00M |
|
$-1.00M |
|
$-1.00M |
|
$-1.00M |
|
$-1.00M |
|
$-1.00M |
|
$-1.00M |
|
$-0.97M |
|
3.38M |
|
3.38M |
|
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$4.72M |
|
$0.37M |
|
$0.37M |
|
$5.09M |
|
$0.72M |
|
-- |
|
-- |
|
$0.72M |
|
$4.37M |
|
$4.37M |
|
$4.37M |
|
3.80M |
|
| Cash Flow Statement Financials | |
$-3.53M |
|
-- |
|
$4.04M |
|
$3.95M |
|
$4.45M |
|
$0.50M |
|
|
Stock-Based Compensation |
$0.07M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.58 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-3.53M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-22.88% |
|
-22.88% |
|
-19.65% |
|
-22.88% |
|
$1.15 |
|
$-1.05 |
|
$-1.05 |
|